Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/33767

SARS-CoV-2 Infection in Multiple Sclerosis. Results of the Spanish Neurology Society Registry


Thumbnail

View/Open:
 SARS-CoV-2 Infection in Multiple Sclerosis.pdf

290,55 kB
Adobe PDF
Share:
Title:
SARS-CoV-2 Infection in Multiple Sclerosis. Results of the Spanish Neurology Society Registry
Authors:
Arrambide, Georgina
Llaneza-González, Miguel Ángel
Costa-Frossard França, Lucienne  
Meca-Lallana, Virginia  
Fernández- Díaz, Eva
Moreno Torres, Irene  
García-Domínguez, Jose Manuel
Ortega Suero, Gloria  
Ayuso-Peralta, Lucia  
Gomez-Moreno, Mayra  
Sotoca-Fernández, Javier J.
Caminero-Rodríguez, Ana Belén
Rodríguez de Antonio, Luis A.
Corujo-Suárez, Marcial
Otano-Martínez, María A.
Pérez-Miralles, Francisco Carlos
Reyes-Garrido, Virginia
Ayuso-Blanco, Teresa
Balseiro-Gómez, José Jesús
Muñoz Pasadas, Mercedes  
Pérez-Molina, Inmaculada
Arnal-García, Carmen
Domingo-Santos, Angela
Guijarro-Castro, Cristina  
Íñiguez-Martínez, Cristina
Téllez Lara, Nieves
Castellanos Pinedo, Fernando  
Castillo-Trivino, Tamara  
Cerdán-Santacruz, Debora María
Perez-Sempere, Angel  
Sebastián Torres, Berta
Álvarez de Arcaya, Amaya
Costa-Arpín, Eva
Durán-Ferreras, Eduardo
Fragoso-Martínez, Marta
González Platas, Montserrat  
Landete, Lamberto  
Millán-Pascual, Jorge
Oreja-Guevara, Celia
MECA-LALLANA, JOSE EUSTASIO  
Editor:
Wolters Kluwer Health/Lippincott Williams & Wilkins
Department:
Departamentos de la UMH::Medicina Clínica
Issue Date:
2021
URI:
https://hdl.handle.net/11000/33767
Abstract:
Objective To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of diseasemodifying treatments. Methods Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Results Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04–1.17) as the only independent risk factor for a fatal outcome. Conclusions This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.
Keywords/Subjects:
Esclerosis múltiple
COVID-19
Knowledge area:
CDU: Ciencias aplicadas: Medicina
Type of document:
application/pdf
Access rights:
info:eu-repo/semantics/openAccess
DOI:
https://doi.org/10.1212/NXI.0000000000001024
Appears in Collections:
Artículos Medicina Clínica



Creative Commons ???jsp.display-item.text9???